All In Biotech

Drug Trial Radar · NCT06593600

Study of Natriuretic Peptide Receptor 1 (NPR1) Antagonist in Adult Patients With Postural Orthostatic Tachycardia Syndrome (POTS)

A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome

Last checked: Nov 19, 2026Latest source record: Jul 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

82

Actual

Start

Nov 13, 2024

Primary completion

May 6, 2026

Study completion Jul 8, 2026

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Sep 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is researching an experimental drug called REGN7544 (called "study drug"). The study is focused on participants with POTS. The aim of the study is to see how safe, tolerable, and effective the study drug is. The study is looking at several other research questions, including: * How the study drug changes heart rate and blood pressure in participants with POTS * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects) * How the study drug affects symptoms associated with POTS

Conditions

  • Postural Orthostatic Tachycardia Syndrome (POTS)

Interventions

  • REGN7544Drug

    Subcutaneous (SC) administration

  • PlaceboDrug

    SC administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Heart Rate (HR) from supine to standing (DeltaHR)Time frame: At Day 8
  2. Change from baseline in DeltaHR-avgTime frame: At day 29

Locations

16 sites in 2 countries. Site status is shown where the registry gives one.

  • Mercy Gilbert Medical Center

    Gilbert, Arizona

  • North County Neurology Associates

    Carlsbad, California

  • Stanford University

    Palo Alto, California

  • Southern California Heart Specialists

    Pasadena, California

  • Yale University

    New Haven, Connecticut

  • Innovative Research of West Florida, Inc.

    Clearwater, Florida

  • Indiana University Health Neuroscience Center

    Indianapolis, Indiana

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Mayo Clinic

    Rochester, Minnesota

  • Saint Luke's MidAmerica Heart Institute

    Kansas City, Missouri

  • New York University Langone

    New York, New York

  • University of Oklahoma Health Sciences Center

    Oklahoma City, Oklahoma

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • University of Texas Southwestern

    Dallas, Texas

  • University of Utah

    Salt Lake City, Utah

  • University of Calgary

    Calgary, Alberta, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.